Canadian researchers conducted a clinical trial at three academic centers in Alberta, Canada. The trial included 116 adult patients with recurrent C. diff, enrolled between October 2014 and September 2016, with follow-up through December 2016.
Of the 116 patients, 105 completed the trial with 57 patients assigned to the capsule group and 59 to the colonoscopy group.
The study shows that prevention of recurrent C. diff was achieved in 96.2 percent of patients in both the capsule group and the colonoscopy group. One patient in each group died of underlying cardiopulmonary illness unrelated to FMT.
Additionally, researchers found that rates of minor adverse events were 5.4 percent for the capsule group as compared to 12.5 percent for the colonoscopy group. Around 66 percent of patients in the capsule group rated their experience as “not at all unpleasant” versus 44 percent in the colonoscopy group.
“Among adults with RCDI, FMT via oral capsules was not inferior to delivery by colonoscopy for preventing recurrent infection over 12 weeks,” study authors concluded.
More articles on healthcare quality:
3 to 4 cups of coffee a day linked to lower all cause mortality risk
Jewish Hospital completes rare 6-part kidney transplant
Harbor Oaks Hospital allegedly inflated staffing levels in anticipation of audit
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
